ANTHEM vs CHANDAN: Stock Comparison

ANTHEM BIOSCIENCES vs CHANDANUpdated 18 Sept 26, 4:08 PM ISTNSE & company filings

ANTHEM BIOSCIENCES is the larger company by market capitalisation. ANTHEM BIOSCIENCES shows a higher ROE, a higher dividend yield and faster revenue growth, while CHANDAN shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ANTHEM leads 9; CHANDAN leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ANTHEMCHANDAN

Valuation lens

What price are you paying?

Market CapContext only
₹53,522 Cr
₹495 Cr
P/E RatioCHANDAN has the lower reading
92.68x
22.4x
P/B RatioCHANDAN has the lower reading
17.54x
3.55x
EPSCHANDAN has the higher reading
₹1.81
₹2.74
Book ValueContext only
₹54
₹72.1
Dividend YieldANTHEM has the higher reading
0.21%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ANTHEM is the larger company
₹53,522 Cr vs ₹495 Cr
P/E Ratio
CHANDAN has a lower P/E
22.4x vs 92.68x
P/B Ratio
CHANDAN has a lower P/B
3.55x vs 17.54x
EPS
CHANDAN has higher earnings per share
₹2.74 vs ₹1.81
Dividend Yield
ANTHEM has a higher dividend yield
0.21% vs 0%
Revenue Growth (TTM YoY)
ANTHEM has faster revenue growth
26.4% vs 0%
EPS Growth (TTM YoY)
ANTHEM has faster EPS growth
127.2% vs 0%
Qtr Sales Growth
ANTHEM has stronger quarterly sales growth
-8.22% vs -39.81%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricANTHEMCHANDAN
SectorHealthcare
IndustryBiotechnology

Price

MetricANTHEMCHANDAN
Live Price₹928.5
Day Change0.12%
Volume54.9 L
52-Week High₹977.55
52-Week Low₹579.15
Distance from 52W High-5.02%

Valuation

MetricANTHEMCHANDAN
Market Cap₹53,522 Cr₹495 Cr
P/E Ratio92.68x22.4x
P/B Ratio17.54x3.55x
EPS₹1.81₹2.74
Book Value₹54₹72.1
Dividend Yield0.21%0%

Growth

MetricANTHEMCHANDAN
Revenue Growth (TTM YoY)26.4%0%
EPS Growth (TTM YoY)127.2%0%
Qtr Sales Growth-8.22%-39.81%
Qtr Profit Growth-14.95%-10.49%

Profitability & Leverage

MetricANTHEMCHANDAN
ROE21.06%16.2%
ROCE22.79%14.55%
Net Margin26.05%0%
Operating Margin43.54%15.97%
Debt to Equity0.01x0.3x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricANTHEMCHANDAN
Promoter Holding71.42% 3.26 pp49.61% 0.06 pp
FII Holding2.58% 1.3 pp0.01%
DII Holding13.48% 1.93 pp5.09% 0.06 pp
Public Holding12.53% 0.03 pp45.29% 0.13 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ANTHEM BIOSCIENCES and CHANDAN.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.